Dr Bob Li, Physician Ambassador to China and Asia-Pacific, Memorial Sloan Kettering Cancer Center and C4C Task Force member, speaks at the 2023 Bloomberg New Economy Forum in Singapore.
Less Than 5% Of Cancer Patients Get Access To Clinical Trials
Forbes.com, September 20, 2023
C4C’s Dr. Bob Li discusses the need for a greater focus on global inequity, defined as a lack of access to clinical trials and breakthrough research. Today, only less than 5% of cancer patients have access to clinical trials offering potentially life-saving new drugs and treatment breakthroughs.
Information on Clinical Trials
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.
How to Join a Clinical Trial
Use these steps as a guide to finding and enrolling in a cancer clinical trial.
The Importance of Patient-Centric Clinical Trials
Working to Improve Patient Access to Clinical Trials
Clinical trials are widely recognized as the best form of cancer care, providing access to the latest breakthroughs science can provide.
But only 2-8% of cancer patients gain access to these trials, due to a combination of factors. The COVID-19 pandemic has led to a revolution in how cancer trials are conducted, decentralizing them from major cities and academic medical institutions, and making them available to more diverse populations of cancer patients around the world. This model can help accelerate breakthroughs.
Cure4Cancer is talking to policymakers around the world to increase access to the latest treatments and to standardize the approval processes so that the whole world can benefit from the latest treatments. Add your voice by joining us on social media or writing a letter to your local representative.
Reimagining Patient-Centric Cancer Clinical Trials
Nature MedicineThe Bloomberg New Economy International Cancer Coalition brings together academia, industry, government, patient advocacy and policy think tanks to leverage technology and collaboration to improve patient access to clinical trials…